查看其它语言版本

Imugene Limited

ASX:IMU ISIN:AU000000IMU9

Imugene Limited ASX IMUImugene Limited (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

     

新闻

2010年9月16日澳洲股市:Conquest Mining Limited (ASX:CQT)与山东国大黄金股份有限公司签订金银铜承销合同

🕔9/16/2010 1:30:08 PM 9034

2010年9月16日澳洲股市报告包括:Conquest Mining(ASX:CQT)与山东国大黄金股份有限公司签订Mt Carlton项目的V2矿生产的金银铜的承销合同;Heemskirk Consolidated Limited (ASX:HSK)宣布与Conquest Mining Limited (ASX:CQT)签订了一份协议;Imugene Limited (ASX:IMU)今天宣布,已在美国一家猪试验专业机构成功完成猪繁殖与呼吸综合症(PRRS)疫苗的第二次试验;Synthesis Energy Systems Inc. (NASDAQ:SYMX) 和Coalworks Limited (ASX:CWK)今天联合发表了题为“利用U-GAS(R)和MTG甲醇制汽油技术,以Oaklands煤生产液体燃料”的报告。

阅读全文
###

58,398 公司背景浏览

  • 本页浏览人次: (过去7日: 9) (过去30日: 28) (自发布以来: 7060) 

公司详细信息

    总部
  • Suite 1, 1233 High Street
    Armadale, VIC 3143
    Australia
  • 电话
  • +61-3-9824-5254 
  • 传真
  • +61-3-9822-7735 
  • 主要部门
  • 医疗-制药 
  • 支柱产业
  • 生物科技 
  • 主页
  • www.imugene.com

社会化媒体